Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis.
Therapeutic Advances in Psychopharmacology 2025 Ahmed Elmosalamy, Idil Tarikogullari, Liliana Patarroyo-Rodriguez et al. 7 citations
Depression affects approximately 5.7% of adults worldwide, and around one-third of these individuals develop treatment-resistant depression (TRD). Intravenous (IV) ketamine and esketamine (administered IV or intranasally (IN)) are novel treatment options for TRD; however, only IN esketamine currently holds FDA approval. Compare the acute effectiveness of IV ketamine with esketamine (IV or IN)...